Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

XML

Spondyloarthritis

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Online download statistics by month:

Online download statistics by month: May 2020 to December 2022

	Abstract	Full	Pdf
May 2020	1067	1039	475
Jun 2020	684	701	227
Jul 2020	339	333	166
Aug 2020	148	147	127
Sep 2020	147	140	85
Oct 2020	240	238	163
Nov 2020	243	237	192
Dec 2020	209	205	140
Jan 2021	150	144	99
Feb 2021	155	134	129
Mar 2021	160	116	100
Apr 2021	118	106	114
May 2021	114	104	73
Jun 2021	135	129	84
Jul 2021	119	114	67
Aug 2021	78	75	57
Sep 2021	88	86	40
Oct 2021	128	127	69
Nov 2021	121	113	88
Dec 2021	118	118	50
Jan 2022	79	79	50
Feb 2022	92	89	41
Mar 2022	124	80	36
Apr 2022	119	114	78
May 2022	96	90	67
Jun 2022	76	81	39
Jul 2022	54	55	30
Aug 2022	70	64	22
Sep 2022	92	87	56
Oct 2022	96	88	48
Nov 2022	57	54	26
Dec 2022	67	58	31
Total	5583	5345	3069